Literature DB >> 7695327

Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

R Malinverni1, C C Kuo, L A Campbell, A Lee, J T Grayston.   

Abstract

We studied the effects of two antibiotic regimens on the course of Chlamydia pneumoniae infection in the lungs of Swiss Webster mice. After intranasal challenge with isolates AR-388 (1.3 x 10(7) inclusion-forming units per mouse) and AR-39 (1.5 x 10(6) inclusion-forming units per mouse), groups of animals were treated with either doxycycline (10 mg/kg of body weight once a day for 3 days), azithromycin (10 mg/kg [single dose]), or saline. Responses were assessed by the isolation of organisms in cell culture, detection of TWAR DNA in lung tissues by PCR, and lung histology. Both regimens were effective in clearing infections induced by AR-388 (P = 0.02 and 0.007 for doxycycline and azithromycin, respectively) compared with controls. TWAR DNA was detected in 77 and 25% of culture-negative lungs 2 weeks after treatment of AR-388 and AR-39 infections, respectively. Histological changes showed interstitial pneumonitis and were similar over time for all groups. Single-dose azithromycin produced drug levels in lung tissues above the MICs for the test strains for a period three times longer than that of single-dose doxycycline. We concluded that short-term antibiotic regimens were successful for the treatment of experimental TWAR pneumonitis in mice. TWAR DNA was frequently recovered from lung tissues after apparently successful treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695327      PMCID: PMC162482          DOI: 10.1128/AAC.39.1.45

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Identification of a new group of Chlamydia psittaci strains called TWAR.

Authors:  C C Kuo; H H Chen; S P Wang; J T Grayston
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

2.  Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

Authors:  P Saikku; M Leinonen; K Mattila; M R Ekman; M S Nieminen; P H Mäkelä; J K Huttunen; V Valtonen
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

3.  In vitro drug susceptibility of Chlamydia sp. strain TWAR.

Authors:  C C Kuo; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

4.  Chronicity and recurrence of psittacosis.

Authors:  P Bowman; J C Wilt; H Sayed
Journal:  Can J Public Health       Date:  1973-03

Review 5.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

6.  Nonculture methods for diagnosing chlamydial infection in patients with trachoma: a clue to the pathogenesis of the disease?

Authors:  J Schachter; J Moncada; C R Dawson; J Sheppard; P Courtright; M E Said; S Zaki; S F Hafez; A Lorincz
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

7.  Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection.

Authors:  A E Girard; D Girard; J A Retsema
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

8.  Pneumonia associated with the TWAR strain of Chlamydia.

Authors:  T J Marrie; J T Grayston; S P Wang; C C Kuo
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391

Review 9.  Treatment of sexually transmitted chlamydial infections.

Authors:  L L Sanders; H R Harrison; A E Washington
Journal:  JAMA       Date:  1986-04-04       Impact factor: 56.272

10.  Importance of reinfection in the pathogenesis of trachoma.

Authors:  J T Grayston; S P Wang; L J Yeh; C C Kuo
Journal:  Rev Infect Dis       Date:  1985 Nov-Dec
View more
  15 in total

1.  Glucocorticoids increase in vitro and in vivo activities of antibiotics against Chlamydophila pneumoniae.

Authors:  Dario Caronzolo; Valeria Lucini; Marilou Pannacci; Silvia Grosso; Federica Colleoni; Franco Fraschini; Francesco Scaglione
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Ana María Ríos; Mónica Fonseca-Aten; Asunción Mejías; Susana Chávez-Bueno; Kathy Katz; Ana María Gómez; George H McCracken; Octavio Ramilo; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Ultrastructural Analysis of Chlamydia Pneumoniae in the Alzheimer's Brain.

Authors:  E James Arking; Denah M Appelt; J Todd Abrams; Sonya Kolbe; Alan P Hudson; Brian J Balin
Journal:  Pathogenesis (Amst)       Date:  1999

4.  In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.

Authors:  H M Freidank; P Losch; H Vögele; M Wiedmann-Al-Ahmad
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

5.  Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis.

Authors:  K Wolf; R Malinverni
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.

Authors:  J Plouffe; D B Schwartz; A Kolokathis; B W Sherman; P M Arnow; J A Gezon; B Suh; A Anzuetto; R N Greenberg; M Niederman; J A Paladino; J A Ramirez; J Inverso; C A Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

7.  Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice.

Authors:  X X Bin; K Wolf; T Schaffner; R Malinverni
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

8.  Effect of PEX, a noncatalytic metalloproteinase fragment with integrin-binding activity, on experimental Chlamydophila pneumoniae infection.

Authors:  Dario Caronzolo; Valeria Lucini; Marilou Pannacci; Silvia Grosso; Nelly Kieffer; Lorenzo Bello; Andreas Bikfalvi; Francesco Scaglione
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

9.  Relevance of Chlamydia pneumoniae murine pneumonitis model to evaluation of antimicrobial agents.

Authors:  N D Masson; C D Toseland; A S Beale
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Chlamydia pneumoniae Infection and Inflammatory Diseases.

Authors:  Rebecca A Porritt; Timothy R Crother
Journal:  For Immunopathol Dis Therap       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.